skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Role of Peroxiredoxin I in Rectal Cancer and Related to p53 Status

Abstract

Background: Neoadjuvant chemoradiotherapy is widely accepted for the treatment of localized rectal cancer. Although peroxiredoxin I (PrxI) and p53 have been implicated in carcinogenesis and cancer treatment, the role of PrxI and its interaction with p53 in the prognosis and treatment response of rectal cancer remain relatively unstudied. Methods and Materials: In the present study, we examined the levels of PrxI and p53 in rectal cancer patients using membrane arrays and compared them with normal population samples. To demonstrate the biologic changes after manipulation of PrxI expression, we established stable transfectants of HCT-116 (wild-type p53) and HT-29 (mutant p53) cells with a PrxI silencing vector. The predictive capacities of PrxI and p53 were also assessed by relating the immunohistochemical staining of a retrospective series of rectal cancer cases to the clinical outcome. Results: The membrane array and immunochemical staining data showed that PrxI, but not p53, was significantly associated with the tumor burden. Our immunochemistry findings further indicated that PrxI positivity was linked to a poor response to neoadjuvant therapy and worse survival. In cellular and animal experiments, the inhibition of PrxI significantly decreased tumor growth and sensitized the tumor to irradiation, as indicated by a lower capacity to scavengemore » reactive oxygen species and more extensive DNA damage. The p53 status might have contributed to the difference between HCT-116 and HT-29 after knockdown of PrxI. Conclusion: According to our data, the level of PrxI combined with the p53 status is relevant to the prognosis and the treatment response. We suggested that PrxI might be a new biomarker for rectal cancer.« less

Authors:
 [1];  [1];  [2];  [1]; ;  [1];  [3];  [1]
  1. Chang Gung University College of Medicine and Chang Gung Institute of Technology, Taiwan (China)
  2. Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan (China)
  3. Department of Pathology, Chang Gung Memorial Hospital, Taiwan (China)
Publication Date:
OSTI Identifier:
21438020
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 78; Journal Issue: 3; Other Information: DOI: 10.1016/j.ijrobp.2010.05.025; PII: S0360-3016(10)00748-0; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTINEOPLASTIC DRUGS; BIOLOGICAL MARKERS; COMBINED THERAPY; NEOPLASMS; RECTUM; BODY; DIGESTIVE SYSTEM; DISEASES; DRUGS; GASTROINTESTINAL TRACT; INTESTINES; LARGE INTESTINE; MEDICINE; ORGANS; THERAPY

Citation Formats

Chen, Miao-Fen, Department of Radiation Oncology, Chang Gung Memorial Hospital, Taiwan, Lee, Kuan-Der, Department of Hematology and Oncology, Chang Gung Memorial Hospital, Taiwan, Yeh, Chung-Hung, Chen, Wen-Cheng, Department of Radiation Oncology, Chang Gung Memorial Hospital, Taiwan, Huang, Wen-Shih, Chin, Chih-Chien, Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan, Lin, Paul- Yang, Wang, Jeng-Yi, and Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan. Role of Peroxiredoxin I in Rectal Cancer and Related to p53 Status. United States: N. p., 2010. Web. doi:10.1016/j.ijrobp.2010.05.025.
Chen, Miao-Fen, Department of Radiation Oncology, Chang Gung Memorial Hospital, Taiwan, Lee, Kuan-Der, Department of Hematology and Oncology, Chang Gung Memorial Hospital, Taiwan, Yeh, Chung-Hung, Chen, Wen-Cheng, Department of Radiation Oncology, Chang Gung Memorial Hospital, Taiwan, Huang, Wen-Shih, Chin, Chih-Chien, Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan, Lin, Paul- Yang, Wang, Jeng-Yi, & Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan. Role of Peroxiredoxin I in Rectal Cancer and Related to p53 Status. United States. https://doi.org/10.1016/j.ijrobp.2010.05.025
Chen, Miao-Fen, Department of Radiation Oncology, Chang Gung Memorial Hospital, Taiwan, Lee, Kuan-Der, Department of Hematology and Oncology, Chang Gung Memorial Hospital, Taiwan, Yeh, Chung-Hung, Chen, Wen-Cheng, Department of Radiation Oncology, Chang Gung Memorial Hospital, Taiwan, Huang, Wen-Shih, Chin, Chih-Chien, Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan, Lin, Paul- Yang, Wang, Jeng-Yi, and Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan. 2010. "Role of Peroxiredoxin I in Rectal Cancer and Related to p53 Status". United States. https://doi.org/10.1016/j.ijrobp.2010.05.025.
@article{osti_21438020,
title = {Role of Peroxiredoxin I in Rectal Cancer and Related to p53 Status},
author = {Chen, Miao-Fen and Department of Radiation Oncology, Chang Gung Memorial Hospital, Taiwan and Lee, Kuan-Der and Department of Hematology and Oncology, Chang Gung Memorial Hospital, Taiwan and Yeh, Chung-Hung and Chen, Wen-Cheng and Department of Radiation Oncology, Chang Gung Memorial Hospital, Taiwan and Huang, Wen-Shih and Chin, Chih-Chien and Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan and Lin, Paul- Yang and Wang, Jeng-Yi and Department of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taiwan},
abstractNote = {Background: Neoadjuvant chemoradiotherapy is widely accepted for the treatment of localized rectal cancer. Although peroxiredoxin I (PrxI) and p53 have been implicated in carcinogenesis and cancer treatment, the role of PrxI and its interaction with p53 in the prognosis and treatment response of rectal cancer remain relatively unstudied. Methods and Materials: In the present study, we examined the levels of PrxI and p53 in rectal cancer patients using membrane arrays and compared them with normal population samples. To demonstrate the biologic changes after manipulation of PrxI expression, we established stable transfectants of HCT-116 (wild-type p53) and HT-29 (mutant p53) cells with a PrxI silencing vector. The predictive capacities of PrxI and p53 were also assessed by relating the immunohistochemical staining of a retrospective series of rectal cancer cases to the clinical outcome. Results: The membrane array and immunochemical staining data showed that PrxI, but not p53, was significantly associated with the tumor burden. Our immunochemistry findings further indicated that PrxI positivity was linked to a poor response to neoadjuvant therapy and worse survival. In cellular and animal experiments, the inhibition of PrxI significantly decreased tumor growth and sensitized the tumor to irradiation, as indicated by a lower capacity to scavenge reactive oxygen species and more extensive DNA damage. The p53 status might have contributed to the difference between HCT-116 and HT-29 after knockdown of PrxI. Conclusion: According to our data, the level of PrxI combined with the p53 status is relevant to the prognosis and the treatment response. We suggested that PrxI might be a new biomarker for rectal cancer.},
doi = {10.1016/j.ijrobp.2010.05.025},
url = {https://www.osti.gov/biblio/21438020}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 3,
volume = 78,
place = {United States},
year = {Mon Nov 01 00:00:00 EDT 2010},
month = {Mon Nov 01 00:00:00 EDT 2010}
}